ENFLONSIA™ (clesrovimab)
搜索文档
Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season
Businesswire· 2025-09-19 10:50
药品监管进展 - 默沙东ENFLONSIA(clesrovimab)获得欧盟CHMP积极意见 用于预防婴儿首个呼吸道合胞病毒季节的RSV感染 [1] 产品适应症 - 该药物针对呼吸道合胞病毒(RSV)的预防性治疗 目标人群为首次面临RSV感染季节的婴儿群体 [1]
